NEW YORK, NY and CAMBRIDGE, MA / April 7, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the nonprofit scientific research organization IAVI today announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats. These diseases - HIV/AIDS, tuberculosis (TB), antimicrobial-resistant enteric infections, and COVID-19 - are estimated to have caused at least 95 million new infections and more than 4 million deaths in 2020 alone. The collaboration combines the power of Moderna's mRNA platform and IAVI's expertise in discovery and product development to advance vaccines and antibodies designed to be globally accessible, especially in low-income countries where the targeted diseases have high incidence and prevalence.

The trial aimed to find whether metformin can reduce the time required for sputum culture to become negative in pulmonary TB patients.

In the two years since covid-19 put the world on pause, the progress the scientific community has made against the disease has been astounding. New vaccines, using new technology, have been developed in record time, and are already in the arms of billions around the world.

The Bill & Melinda Gates Medical Research Institute (MRI) is conducting a TB epidemiology study: setting the stage for a Phase 3 efficacy trial for its investigational TB vaccine.

On 11 April 2022, FIND, the global alliance for diagnostics, TB Alliance and the International AIDS Vaccine Initiative (IAVI) will host a webinar bringing together a panel of experts to review both new and experimental tools that have the potential to end TB for good, and what is needed to bring them to scale and achieve public health impact.

04 April 2022 | Geneva:  Tuberculosis antigen-based skin tests (TBST), a new class of tests to diagnose TB infection, have been evaluated by the World Health Organization (WHO) and are found to be accurate, acceptable, feasible and cost-effective. These tests represent an alternative to tuberculin skin test (TST) and Interferon-Gamma Release Assays (IGRAs).

Every day we see stark images of the war in Ukraine — bombed-out buildings, explosions, and bodies lying in the streets. But there's another, less visible war — against the bacteria and viruses that are gathering their forces together. They, too, will infect parts of the population and may spread throughout Europe. Here's what Ukrainians — and their neighbors — are facing on the infectious disease front.

The World Health Organization’s (WHO) Global TB Program is seeking qualified individuals to serve as members of the Strategic and Technical Advisory Group on TB (STAG-TB).

In a breakthrough for eradication of tuberculosis, the Pune-based National AIDS Research Institute (NARI) under the Indian Council of Medical Research (ICMR) is moving forward with phase 3 trials for a vaccine for TB in healthy household contacts or newly diagnosed positive pulmonary TB patients.

RESIST-TB released its March 2022 newsletter with the latest research publications on drug-resistant TB.